Piramal Pharma Limited (NSE:PPLPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 238.81B -18.3% |
| Revenue (ttm) | 88.69B -3.1% |
| Net Income | -3.26B |
| EPS | -2.46 |
| Shares Out | 1.33B |
| PE Ratio | n/a |
| Forward PE | 130.08 |
| Dividend | 0.14 (0.08%) |
| Ex-Dividend Date | Jul 16, 2025 |
| Volume | 13,876,260 |
| Average Volume | 9,656,361 |
| Open | 177.80 |
| Previous Close | 179.85 |
| Day's Range | 176.04 - 188.40 |
| 52-Week Range | 132.30 - 226.00 |
| Beta | 0.37 |
| RSI | 72.98 |
| Earnings Date | Apr 28, 2026 |
About Piramal Pharma
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, inje... [Read more]
Financial Performance
Financial StatementsNews
Piramal Pharma Transcript: Q4 25/26
FY 2026 saw revenue and EBITDA decline due to external headwinds, but underlying growth was resilient after adjusting for destocking. Early to mid-teens revenue growth is guided for FY 2027, with EBITDA and PAT expected to grow faster, supported by strong CDMO order inflows and ongoing investments.
Piramal Pharma Transcript: Q3 25/26
Q3 FY26 saw a 3%-4% revenue decline, but early recovery signs emerged with improved US biopharma funding and order inflows. The Kenalog acquisition and ongoing capacity expansions support long-term growth, while guidance for FY27 and 2030 remains intact.
Piramal Pharma Transcript: Q2 25/26
Revenue and EBITDA declined year-over-year due to a major CDMO customer’s inventory destocking, but cost controls and operational excellence partially offset the impact. Guidance for FY 2026 is now flat revenue and low-teens EBITDA margin, with H2 expected to outperform H1. Growth is anticipated from onshore CDMO demand, biopharma funding recovery, and consumer healthcare momentum.
Piramal Pharma Transcript: Q1 25/26
Q1 FY2026 results were in line with guidance, with adjusted revenue showing double-digit growth despite reported declines due to destocking. Consumer Healthcare and overseas CDMO sites drove growth, while margin moderation was expected. Net profit rose 8% YoY.
Piramal Pharma Transcript: Q4 24/25
Annual revenue surpassed $1 billion, up 12% year-over-year, led by CDMO and consumer healthcare growth. FY2026 will see muted growth and margin due to a major customer’s inventory normalization, with a strong rebound expected in FY2027.
Piramal Pharma Transcript: Q3 24/25
Revenue and EBITDA grew strongly year-over-year, led by CDMO and CHG segments, with robust ICH and e-commerce growth. Sustainability initiatives advanced, and guidance for mid-teens growth in FY25 was reiterated, with Q4 expected to be the strongest quarter.
Piramal Pharma Transcript: Q2 24/25
Q2 saw 17% revenue growth and 18% EBITDA margin, led by strong CDMO and ICH performance. Guidance for early teens growth in revenue and EBITDA is reiterated, with H2 expected to outperform H1. Lexington facility expansion and specialty product launches support long-term growth.
Piramal Pharma Transcript: Q1 24/25
Q1 FY25 delivered 12% revenue and 31% EBITDA growth year-over-year, led by strong CDMO and consumer healthcare performance. Net debt-to-EBITDA improved to 2.8x, and FY25 guidance for early teens revenue and EBITDA growth is maintained.